Immunological dysregulation in multiple myeloma microenvironment

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Romano, Alessandra ^a,b,c   Conticello, Concetta ^c   Cavalli, Maide ^c   Vetro, Calogero ^a,c   La Fauci, Alessia ^c   Parrinello, Nunziatina Laura ^a,c   Di Raimondo, Francesco ^a,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b Fondazione Veronesi   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; COLECALCIFEROL; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HISTAMINE; INTERLEUKIN 17; INTERLEUKIN 22; LENALIDOMIDE; PHOSPHODIESTERASE INHIBITOR; POMALIDOMIDE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RETINOL; SILDENAFIL; TADALAFIL; THALIDOMIDE DERIVATIVE; TRITERPENOID; ZOLEDRONIC ACID;

ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DENDRITIC CELL; ERYTHROCYTE; EXTRACELLULAR MATRIX; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MEGAKARYOCYTE; MESENCHYMAL STEM CELL; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYELOMA CELL; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; STEM CELL NICHE; SUPPRESSOR CELL; T LYMPHOCYTE; TH17 CELL; THROMBOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; CARCINOGENESIS; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

BONE MARROW CELLS; CARCINOGENESIS; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84903555075     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/198539     Document Type: Article

References (114)

1. Rajkumar S. V., Buadi F., Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Practice and Research: Clinical Haematology 2007 20 4 665 680 2-s2.0-36749092256 10.1016/j.beha.2007. 10.002 (Pubitemid 350215386)
2. Landgren O., Korde N., Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities. Oncology 2011 25 7 589 590 2-s2.0-80052900724
3. Landgren O., Kyle R. A., Pfeiffer R. M., Katzmann J. A., Caporaso N. E., Hayes R. B., Dispenzieri A., Kumar S., Clark R. J., Baris D., Hoover R., Rajkumar S. V., Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009 113 22 5412 5417 2-s2.0-67049162188 10.1182/blood-2008-12-194241
4. Brousseau M., Leleu X., Gerard J., Gastinne T., Godon A., Genevieve F., Dib M., Lai J.-L., Facon T., Zandecki M., Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clinical Cancer Research 2007 13 20 6026 6031 2-s2.0-35948992626 10.1158/1078-0432.CCR-07-0031 (Pubitemid 350075058)
5. Chiecchio L., Dagrada G. P., Ibrahim A. H., Cabanas E. D., Protheroe R. K. M., Stockley D. M., Orchard K. H., Cross N. C. P., Harrison C. J., Ross F. M., Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009 94 12 1708 1713 2-s2.0-73149102074 10.3324/haematol.2009.011064
6. Agarwal A., Ghobrial I. M., Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clinical Cancer Research 2013 19 5 985 994 2-s2.0-84874865836 10.1158/1078-0432.CCR-12-2922
7. Fowler J. A., Mundy G. R., Lwin S. T., Edwards C. M., Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Research 2012 72 9 2183 2189 2-s2.0-84860537254 10.1158/0008-5472.CAN-11-2067
8. Nefedova Y., Landowski T. H., Dalton W. S., Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003 17 6 1175 1182 2-s2.0-0038717067 10.1038/sj.leu.2402924 (Pubitemid 36722250)
9. Hughes V., Microenvironment: neighbourhood watch. Nature 2011 480 7377 S48 S49 2-s2.0-83455203493 10.1038/480S48a
10. Mitsiades C. S., Anderson K. C., Carrasco D. R., Mouse models of human myeloma. Hematology/Oncology Clinics of North America 2007 21 6 1051 1069 2-s2.0-35748946662 10.1016/j.hoc.2007.08.003 (Pubitemid 350051346)
11. Li Z.-W., Dalton W. S., Tumor microenvironment and drug resistance in hematologic malignancies. Blood Reviews 2006 20 6 333 342 2-s2.0-33750631842 10.1016/j.blre.2005.08.003 (Pubitemid 44691998)
12. Croese J. W., vas Nunes C. M., Radl J., Van Den Enden-Vieveen M. H. M., Brondijk R. J., Boersma W. J. A., The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. British Journal of Cancer 1987 56 5 555 560 2-s2.0-0023628690 (Pubitemid 17165647)
13. Vanderkerken K., De Raeve H., Goes E., Van Meirvenne S., Radl J., Van Riet I., Thielemans K., Van Camp B., Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. British Journal of Cancer 1997 76 4 451 460 2-s2.0-0030749836 (Pubitemid 27331209)
14. Campbell R. A., Manyak S. J., Yang H. H., Sjak-Shie N. N., Chen H., Gui D., Popoviciu L., Wang C., Gordon M., Pang S., Bonavida B., Said J., Berenson J. R., LAG 1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. International Journal of Oncology 2006 28 6 1409 1417 2-s2.0-33747121704
15. Kovalchuk A. L., Kim J. S., Park S. S., Coleman A. E., Ward J. M., Morse H. C. III, Kishimoto T., Potter M., Janz S., IL-6 transgenic mouse model for extraosseous plasmacytoma. Proceedings of the National Academy of Sciences of the United States of America 2002 99 3 1509 1514 2-s2.0-0037022341 10.1073/pnas.022643999 (Pubitemid 34136523)
16. LeBlanc R., Catley L. P., Hideshima T., Lentzsch S., Mitsiades C. S., Mitsiades N., Neuberg D., Goloubeva O., Pien C. S., Adams J., Gupta D., Richardson P. G., Munshi N. C., Anderson K. C., Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research 2002 62 17 4996 5000 2-s2.0-0036735298 (Pubitemid 34984425)
17. Yaccoby S., Barlogie B., Epstein J., Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998 92 8 2908 2913 2-s2.0-0032532608 (Pubitemid 28469106)
18. Yaccoby S., Epstein J., The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999 94 10 3576 3582 2-s2.0-0033570946 (Pubitemid 29536154)
19. Dewan M. Z., Watanabe M., Terashima K., Aoki M., Sata T., Honda M., Ito M., Yamaoka S., Watanabe T., Horie R., Yamamoto N., Prompt tumor formation and maintenance of constitutive NF- B activity of multiple myeloma cells in NOD/SCID/ γ cnull mice. Cancer Science 2004 95 7 564 568 2-s2.0-4143149779 10.1111/j.1349-7006.2004.tb02487.x (Pubitemid 39089636)
20. Miyakawa Y., Ohnishi Y., Tomisawa M., Monnai M., Kohmura K., Ueyama Y., Ito M., Ikeda Y., Kizaki M., Nakamura M., Establishment of a new model of human multiple myeloma using NOD/SCID/ γ cnull (NOG) mice. Biochemical and Biophysical Research Communications 2004 313 2 258 262 2-s2.0-10744225890 10.1016/j.bbrc.2003.11.120 (Pubitemid 37543579)
21. Tassone P., Neri P., Carrasco D. R., Burger R., Goldmacher V. S., Fram R., Munshi V., Shammas M. A., Catley L., Jacob G. S., Venuta S., Anderson K. C., Munshi N. C., A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005 106 2 713 716 2-s2.0-20344381988 10.1182/blood-2005-01-0373 (Pubitemid 40981270)
22. Yata K., Yaccoby S., The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004 18 11 1891 1897 2-s2.0-8844264524 10.1038/sj.leu.2403513 (Pubitemid 39530021)
23. Calimeri T., Battista E., Conforti F., Neri P., Di Martino M. T., Rossi M., Foresta U., Piro E., Ferrara F., Amorosi A., Bahlis N., Anderson K. C., Munshi N., Tagliaferri P., Causa F., Tassone P., A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011 25 4 707 711 2-s2.0-79954436115 10.1038/leu.2010.300
24. Su J., Zhang L., Zhang W., Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling. PloS ONE 2014 9 1 e85059
25. Groen R. W. J., Noort W. A., Raymakers R. A., Prins H.-J., Aalders L., Hofhuis F. M., Moerer P., Van Velzen J. F., Bloem A. C., Van Kessel B., Rozemuller H., Van Binsbergen E., Buijs A., Yuan H., De Bruijn J. D., De Weers M., Parren P. W. H. I., Schuringa J. J., Lokhorst H. M., Mutis T., Martens A. C. M., Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012 120 3 2-s2.0-84864128108 10.1182/blood-2012-03-414920
26. Basak G. W., Srivastava A. S., Malhotra R., Carrier E., Multiple myeloma bone marrow niche. Current Pharmaceutical Biotechnology 2009 10 3 335 346 2-s2.0-65949095894 10.2174/138920109787847493
27. Manier S., Sacco A., Leleu X., Ghobrial I. M., Roccaro A. M., Bone marrow microenvironment in multiple myeloma progression. Journal of Biomedicine and Biotechnology 2012 2012 5 2-s2.0-84871913165 10.1155/2012/157496 157496
28. Iriuchishima H., Takubo K., Miyakawa Y., Nakamura-Ishizu A., Miyauchi Y., Fujita N., Miyamoto K., Miyamoto T., Ikeda E., Kizaki M., Nojima Y., Suda T., Neovascular niche for human myeloma cells in immunodeficient mouse bone. PloS ONE 2012 7 2 2-s2.0-84856693203 10.1371/journal.pone.0030557 e30557
29. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., Mitsiades C., Munshi N. C., Richardson P. G., Carrasco R. D., Anderson K. C., Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells. Blood 2009 114 5 1046 1052 2-s2.0-70349243697 10.1182/blood-2009-01- 199604
30. Hideshima T., Podar K., Chauhan D., Anderson K. C., Cytokines and signal transduction. Best Practice and Research: Clinical Haematology 2005 18 4 509 524 2-s2.0-22144476861 10.1016/j.beha.2005.01.003 (Pubitemid 40984111)
31. Kim K., Kong S.-Y., Fulciniti M., Li X., Song W., Nahar S., Burger P., Rumizen M. J., Podar K., Chauhan D., Hideshima T., Munshi N. C., Richardson P., Clark A., Ogden J., Goutopoulos A., Rastelli L., Anderson K. C., Tai Y.-T., Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. British Journal of Haematology 2010 149 4 537 549 2-s2.0-77951678924 10.1111/j.1365-2141.2010.08127.x
32. Podar K., Chauhan D., Anderson K. C., Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009 23 1 10 24 2-s2.0-58249101211 10.1038/leu.2008.259
33. Podar K., Richardson P. G., Hideshima T., Chauhan D., Anderson K. C., The malignant clone and the bone-marrow environment. Best Practice and Research in Clinical Haematology 2007 20 4 597 612 2-s2.0-36749011232 10.1016/j.beha.2007. 08.002 (Pubitemid 350215375)
34. Tai Y.-T., Fulciniti M., Hideshima T., Song W., Leiba M., Li X.-F., Rumizen M., Burger P., Morrison A., Podar K., Chauhan D., Tassone P., Richardson P., Munshi N. C., Ghobrial I. M., Anderson K. C., Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 2007 110 5 1656 1663 2-s2.0-34548844157 10.1182/blood-2007-03-081240 (Pubitemid 47443984)
35. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., Munshi N., Dang L., Castro A., Palombella V., Adams J., Anderson K. C., NF- B as a therapeutic target in multiple myeloma. Journal of Biological Chemistry 2002 277 19 16639 16647 2-s2.0-18544367201 10.1074/jbc.M200360200 (Pubitemid 34967682)
36. Moreaux J., Legouffe E., Jourdan E., Quittet P., Rème T., Lugagne C., Moine P., Rossi J.-F., Klein B., Tarte K., BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004 103 8 3148 3157 2-s2.0-11144355586 10.1182/blood-2003-06-1984 (Pubitemid 38451693)
37. Conticello C., Giuffrida R., Adamo L., Anastasi G., Martinetti D., Salomone E., Colarossi C., Amato G., Gorgone A., Romano A., Iannolo G., De Maria R., Giustolisi R., Gulisano M., Di Raimondo F., NF- B localization in multiple myeloma plasma cells and mesenchymal cells. Leukemia Research 2011 35 1 52 60 2-s2.0-78650176111 10.1016/j.leukres.2010.06.023
38. Podar K., Novel targets and derived small molecule inhibitors in multiple Myeloma. Current Cancer Drug Targets 2012 12 7 797 813 2-s2.0-84866371772 10.2174/156800912802429319
39. Zipori D., The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell. Cancer Microenvironment 2010 3 1 15 28 2-s2.0-78649640378 10.1007/s12307-009-0034-7
40. Balakumaran A., Robey P. G., Fedarko N., Landgren O., Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Review of Molecular Diagnostics 2010 10 4 465 480 2-s2.0-77952493512 10.1586/erm.10.31
41. Podar K., Anderson K. C., Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Current Cancer Drug Targets 2011 11 9 1005 1024 2-s2.0-81155126204 10.2174/156800911798073113
42. Fan F., Schimming A., Jaeger D., Podar K., Targeting the tumor microenvironment: focus on angiogenesis. Journal of Oncology 2012 2012 16 2-s2.0-80053483270 10.1155/2012/281261 281261
43. Kumar S., Gertz M. A., Dispenzieri A., Lacy M. Q., Wellik L. A., Fonseca R., Lust J. A., Witzig T. E., Kyle R. A., Greipp P. R., Rajkumar S. V., Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplantation 2004 34 3 235 239 2-s2.0-4344640371 10.1038/sj.bmt.1704555 (Pubitemid 39136830)
44. di Raimondo F., Azzaro M. P., Palumbo G. A., Bagnato S., Giustolisi G., Floridia P. M., Sortino G., Giustolisi R., Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000 85 8 800 805 2-s2.0-0033835945
45. Hu J., van Valckenborgh E., Menu E., de Bruyne E., Vanderkerken K., Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Disease Models and Mechanisms 2012 5 6 763 771 2-s2.0-84870020416 10.1242/dmm.008961
46. Kim J., Denu R. A., Dollar B. A., Escalante L. E., Kuether J. P., Callander N. S., Asimakopoulos F., Hematti P., Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. British Journal of Haematology 2012 158 3 336 346 2-s2.0-84863812218 10.1111/j.1365-2141.2012.09154.x
47. Wong T. W., Kita H., Hanson C. A., Walters D. K., Arendt B. K., Jelinek D. F., Induction of malignant plasma cell proliferation by eosinophils. PloS ONE 2013 8 7 2-s2.0-84880686635 10.1371/journal.pone.0070554 e70554
48. Pratt G., Goodyear O., Moss P., Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology 2007 138 5 563 579 2-s2.0-34547677725 10.1111/j.1365-2141.2007.06705.x (Pubitemid 47208476)
49. Rossi M., Botta C., Correale P., Tassone P., Tagliaferri P., Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opinion on Biological Therapy 2013 13 1, supplement S83 S93 2-s2.0-84879564424 10.1517/14712598.2013.799130
50. Chung D. J., Rossi M., Romano E., Ghith J., Yuan J., Munn D. H., Young J. W., Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009 114 3 555 563 2-s2.0-70149093957 10.1182/blood-2008-11-191197
51. + regulatory T cells: role of B7-H3 expression and antigen presentation. European Journal of Immunology 2007 37 8 2117 2126 2-s2.0-34547894233 10.1002/eji.200636841 (Pubitemid 47250204)
52. Nair J. R., Rozanski C. H., Lee K. P., Under one roof: the bone marrow survival niche for multiple myeloma and normal plasma cells. Oncoimmunology 2012 1 3 388 389
53. Sharma A., Khan R., Joshi S., Kumar L., Sharma M., Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leukemia & Lymphoma 2010 51 5 920 927 2-s2.0-77951820013 10.3109/10428191003699563
54. Chen Z., Lin F., Gao Y., Li Z., Zhang J., Xing Y., Deng Z., Yao Z., Tsun A., Li B., FOXP3 and ROR γ t: transcriptional regulation of Treg and Th17. International Immunopharmacology 2011 11 5 536 542 2-s2.0-79954632692 10.1016/j.intimp.2010.11.008
55. Crome S. Q., Wang A. Y., Levings M. K., Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clinical and Experimental Immunology 2010 159 2 109 119 2-s2.0-72949107811 10.1111/j.1365-2249.2009.04037.x
56. Hoechst B., Gamrekelashvili J., Manns M. P., Greten T. F., Korangy F., Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011 117 24 6532 6541 2-s2.0-79959271214 10.1182/blood-2010-11-317321
57. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., Huang E., Finlayson E., Simeone D., Welling T. H., Chang A., Coukos G., Liu R., Zou W., Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009 114 6 1141 1149 2-s2.0-69849107597 10.1182/blood-2009-03-208249
58. Lee Y. K., Mukasa R., Hatton R. D., Weaver C. T., Developmental plasticity of Th17 and Treg cells. Current Opinion in Immunology 2009 21 3 274 280 2-s2.0-67049097104 10.1016/j.coi.2009.05.021
59. Schmidl C., Hansmann L., Andreesen R., Edinger M., Hoffmann P., Rehli M., Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg. European Journal of Immunology 2011 41 5 1491 1498 2-s2.0-79955166099 10.1002/eji.201041067
60. Maecker B., Anderson K. S., von Bergwelt-Baildon M. S., Weller E., Vonderheide R. H., Richardson P. G., Schlossman R. L., Menezes I. A., Xia Z., Munshi N. C., Anderson K. C., Nadler L. M., Schultze J. L., Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. British Journal of Haematology 2003 121 6 842 848 2-s2.0-0038268128 10.1046/j.1365-2141.2003.04375.x (Pubitemid 36760302)
61. Görgün G., Calabrese E., Soydan E., Hideshima T., Perrone G., Bandi M., Cirstea D., Santo L., Hu Y., Tai Y.-T., Nahar S., Mimura N., Fabre C., Raje N., Munshi N., Richardson P., Anderson K. C., Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010 116 17 3227 3237 2-s2.0-78049386125 10.1182/blood-2010-04-279893
62. Joshua D. E., Brown R. D., Ho P. J., Gibson J., Regulatory T cells and multiple myeloma. Clinical Lymphoma and Myeloma 2008 8 5 283 286 2-s2.0-58149327333 10.3816/CLM.2008.n.039
63. Laronne-Bar-On A., Zipori D., Haran-Ghera N., Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma. Journal of Immunology 2008 181 5 3714 3724 2-s2.0-51549091254
64. + Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. British Journal of Haematology 2009 144 5 686 695 2-s2.0-58849093606 10.1111/j.1365-2141.2008. 07530.x
65. Gupta R., Ganeshan P., Hakim M., Verma R., Sharma A., Kumar L., Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leukemia Research 2011 35 7 874 878 2-s2.0-79958695591 10.1016/j.leukres.2010.11.010
66. Prabhala R. H., Neri P., Bae J. E., Tassone P., Shammas M. A., Allam C. K., Daley J. F., Chauhan D., Blanchard E., Thatte H. S., Anderson K. C., Munshi N. C., Dysfunctional T regulatory cells in multiple myeloma. Blood 2006 107 1 301 304 2-s2.0-30144444962 10.1182/blood-2005-08-3101 (Pubitemid 43053555)
67. Beyer M., Classen S., Endl E., Kochanek M., Weihrauch M. R., Debey-Pascher S., Knolle P. A., Schultze J. L., Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3. Clinical and Developmental Immunology 2011 2011 12 2-s2.0-81555227846 10.1155/2011/734036 734036
68. Favaloro J., Brown R., Aklilu E., Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia & Lymphoma 2013
69. Prabhala R. H., Pelluru D., Fulciniti M., Prabhala H. K., Nanjappa P., Song W., Pai C., Amin S., Tai Y.-T., Richardson P. G., Ghobrial I. M., Treon S. P., Daley J. F., Anderson K. C., Kutok J. L., Munshi N. C., Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010 115 26 5385 5392 2-s2.0-77955862810 10.1182/blood-2009-10-246660
70. Noonan K., Marchionni L., Anderson J., Pardoll D., Roodman G. D., Borrello I., A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010 116 18 3554 3563 2-s2.0-78149322663 10.1182/blood-2010-05-283895
71. Bryant C., Suen H., Brown R., Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal 2013 3, article e148
72. Shen C.-J., Yuan Z.-H., Liu Y.-X., Hu G.-Y., Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma. Journal of International Medical Research 2012 40 2 556 564 2-s2.0-84860476030
73. Dhodapkar K. M., Barbuto S., Matthews P., Kukreja A., Mazumder A., Vesole D., Jagannath S., Dhodapkar M. V., Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008 112 7 2878 2885 2-s2.0-53449089919 10.1182/blood-2008-03-143222
74. Adhikary G., Grun D., Kerr C., Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation. PloS ONE 2013 8 12 e84324
75. Coles S. J., Wang E. C. Y., Man S., Hills R. K., Burnett A. K., Tonks A., Darley R. L., CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011 25 5 792 799 2-s2.0-79955847224 10.1038/leu.2011.1
76. Olteanu H., Harrington A. M., Hari P., Kroft S. H., CD200 expression in plasma cell myeloma. British Journal of Haematology 2011 153 3 408 411 2-s2.0-79954419980 10.1111/j.1365-2141.2010.08555.x
77. Palumbo G. A., Parrinello N., Fargione G., Cardillo K., Chiarenza A., Berretta S., Conticello C., Villari L., Di Raimondo F., CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leukemia Research 2009 33 9 1212 1216 2-s2.0-67649267959 10.1016/j.leukres.2009.01.017
78. Talebian F., Bai X. F., The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy. Oncoimmunology 2012 1 6 971 973
79. Gorczynski R. M., Chen Z., Shivagnahnam S., Taseva A., Wong K., Yu K., Khatri I., Potent immunosuppression by a bivalent molecule binding to CD200R and TGF- β R. Transplantation 2010 90 2 150 159 2-s2.0-77954951434 10.1097/TP.0b013e3181e2d6a1
80. Alapat D., Coviello-Malle J., Owens R., Qu P., Barlogie B., Shaughnessy J. D., Lorsbach R. B., Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. American Journal of Clinical Pathology 2012 137 1 93 100 2-s2.0-84855265260 10.1309/ AJCP59UORCYZEVQO
81. Moreaux J., Hose D., Reme T., Jourdan E., Hundemer M., Legouffe E., Moine P., Bourin P., Moos M., Corre J., Möhler T., De Vos J., Rossi J. F., Goldschmidt H., Klein B., CD200 is a new prognostic factor in multiple myeloma. Blood 2006 108 13 4194 4197 2-s2.0-33845510301 10.1182/blood-2006-06-029355 (Pubitemid 44913292)
82. Conticello C., Giuffrida R., Parrinello N., CD200 expression in patients with Multiple Myeloma: another piece of the puzzle. Leukemia Research 2013 37 12 1616 1621
83. Preston S., Wright G. J., Starr K., Barclay A. N., Brown M. H., The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages. European Journal of Immunology 1997 27 8 1911 1918 2-s2.0-0030744254 10.1002/eji.1830270814 (Pubitemid 27346005)
84. Nagaraj S., Collazo M., Corzo C. A., Youn J.-I., Ortiz M., Quiceno D., Gabrilovich D. I., Regulatory myeloid suppressor cells in health and disease. Cancer Research 2009 69 19 7503 7506 2-s2.0-70350218860 10.1158/0008-5472.CAN- 09-2152
85. Ostrand-Rosenberg S., Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunology, Immunotherapy 2010 59 10 1593 1600 2-s2.0-77955549860 10.1007/s00262-010-0855-8
86. Ostrand-Rosenberg S., Sinha P., Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology 2009 182 8 4499 4506 2-s2.0-65249138393 10.4049/jimmunol.0802740
87. Ramachandran I. R., Martner A., Pisklakova A., Condamine T., Chase T., Vogl T., Roth J., Gabrilovich D., Nefedova Y., Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. Journal of Immunology 2013 190 7 3815 3823 2-s2.0-84875442375 10.4049/jimmunol.1203373
88. Görgün G. T., Whitehill G., Anderson J. L., Hideshima T., Maguire C., Laubach J., Raje N., Munshi N. C., Richardson P. G., Anderson K. C., Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013 121 15 2975 2987 2-s2.0-84879452593 10.1182/blood-2012-08-448548
89. Muthu Raja K. R., Kovarova L., Hajek R., Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leukemia & Lymphoma 2012 53 7 1406 1408 2-s2.0-84862742268 10.3109/10428194.2011.652106
90. -/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scandinavian Journal of Immunology 2010 72 6 540 547 2-s2.0-78149270433 10.1111/j.1365-3083.2010.02463.x
91. +HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma. Blood 2011 117 3 872 881 2-s2.0-78751689059 10.1182/blood-2010-05-283820
92. Serafini P., Borrello I., Bronte V., Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology 2006 16 1 53 65 2-s2.0-31344474166 10.1016/j.semcancer.2005.07.005 (Pubitemid 43139709)
93. van Valckenborgh E., Schouppe E., Movahedi K., De Bruyne E., Menu E., De Baetselier P., VanDerkerken K., Van GinDerachter J. A., Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-Derived suppressor cell subpopulations in the bone marrow. Leukemia 2012 26 11 2424 2428 2-s2.0-84869093412 10.1038/leu.2012.113
94. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Gomez A. F., Mesa C., Geilich M., Winkels G., Traggiai E., Casati A., Grassi F., Bronte V., Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. European Journal of Immunology 2010 40 1 22 35 2-s2.0-74249101123 10.1002/eji.200939903
95. Favaloro J., Liyadipitiya T., Brown R., Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leukemia & Lymphoma 2014
96. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004 6 4 409 421 2-s2.0-5444225991 10.1016/j.ccr.2004.08.031 (Pubitemid 39361441)
97. + myeloid-derived suppressor cells: formidable partners in tumor metastasis. Journal of Bone and Mineral Research 2010 25 8 1701 1706 2-s2.0-77955719466 10.1002/jbmr.154
98. Sawant A., Deshane J., Jules J., Lee C. M., Harris B. A., Feng X., Ponnazhagan S., Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Research 2013 73 2 672 682 2-s2.0-84872554724 10.1158/0008-5472.CAN-12-2202
99. Melani C., Sangaletti S., Barazzetta F. M., Werb Z., Colombo M. P., Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research 2007 67 23 11438 11446 2-s2.0-37049006066 10.1158/0008-5472.CAN-07-1882 (Pubitemid 350248572)
100. Wesolowski R., Markowitz J., Carson W., Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer. Journal For ImmunoTherapy of Cancer 2013 1 1, article 10
101. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., Borrello I., Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal of Experimental Medicine 2006 203 12 2691 2702 2-s2.0-33751531874 10.1084/jem.20061104 (Pubitemid 44833345)
102. Rudraraju L., Ye X., Noonan K., Huff C. A., Borrello I. M., Administration of an oral PDE5 inhibitor, tadalafil In conjunction with a lenalidomide containing regimen in patients with multiple myeloma. Blood 2013 122 21, article 1959
103. Noonan K. A., Ghosh N., Rudraraju L., Bui M., Borrello I., Targeting immune suppression with PDE-5 inhibition in end stage multiple myeloma: a case study. Cancer Immunology Research 2014
104. Mitsiades N., Mitsiades C. S., Poulaki V., Chauhan D., Richardson P. G., Hideshima T., Munshi N., Treon S. P., Anderson K. C., Biologic sequelae of nuclear factor- B blockade in multiple myeloma: therapeutic applications. Blood 2002 99 11 4079 4086 2-s2.0-0036624741 10.1182/blood.V99.11.4079 (Pubitemid 35332050)
105. Sakamaki I., Kwak L. W., Cha S.-C., Yi Q., Lerman B., Chen J., Surapaneni S., Bateman S., Qin H., Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 2013 2-s2.0-84879762749 10.1038/leu.2013.177
106. Zitvogel L., Galluzzi L., Smyth M., Kroemer G., Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013 39 1 74 88 2-s2.0-84880747672 10.1016/j.immuni.2013.06.014
107. Liu P., Jaffar J., Hellstrom I., Hellstrom K. E., Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. Journal of Immunotherapy 2010 33 1 53 59 2-s2.0-74349102406 10.1097/CJI.0b013e3181b56af4
108. Sistigu A., Viaud S., Chaput N., Bracci L., Proietti E., Zitvogel L., Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Seminars in immunopathology 2011 33 4 369 383 2-s2.0-84855729397
109. Alizadeh D., Trad M., Hanke N. T., Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T cell transfer in breast cancer. Cancer Research 2013
110. Terpos E., Berenson J., Raje N., Roodman G. D., Management of bone disease in multiple myeloma. Expert Review of Hematology 2014 7 1 113 125
111. Morgan G. J., Davies F. E., Gregory W. M., Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clinical Cancer Research 2013 19 21 6030 6038
112. Avilés A., Neri N., Huerta-Guzmán J., Nambo M. J., Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Current Oncology 2013 20 1 e13 e20 2-s2.0-84873502317 10.3747/co.20.1055
113. Witzig T. E., Laumann K. M., Lacy M. Q., Hayman S. R., Dispenzieri A., Kumar S., Reeder C. B., Roy V., Lust J. A., Gertz M. A., Greipp P. R., Hassoun H., Mandrekar S. J., Rajkumar S. V., A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2013 27 1 220 225 2-s2.0-84873566851 10.1038/leu.2012.236
114. Porembka M. R., Mitchem J. B., Belt B. A., Hsieh C.-S., Lee H.-M., Herndon J., Gillanders W. E., Linehan D. C., Goedegebuure P., Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunology, Immunotherapy 2012 61 9 1373 1385 2-s2.0-84866537713 10.1007/s00262-011-1178-0